Author
Zoë Hyde
Other affiliations: Curtin University
Bio: Zoë Hyde is an academic researcher from University of Western Australia. The author has contributed to research in topics: Population & Testosterone (patch). The author has an hindex of 26, co-authored 46 publications receiving 2254 citations. Previous affiliations of Zoë Hyde include Curtin University.
Papers
More filters
TL;DR: In older men, lower total testosterone levels predict increased incidence of stroke or TIA after adjusting for conventional risk factors for cardiovascular disease.
Abstract: Context: Lower circulating testosterone concentrations are associated with metabolic syndrome, type 2 diabetes, carotid intima-media thickness, and aortic and lower limb arterial disease in men. However, it is unclear whether lower testosterone levels predict major cardiovascular events. Objective: We examined whether lower serum testosterone was an independently significant risk factor for symptomatic cerebrovascular events in older men. Design: This was a prospective observational study with median follow-up of 3.5 yr. Setting: Community-dwelling, stroke-free older men were studied. Participants: A total of 3443 men at least 70 yr of age participated in the study. Main Outcome Measures: Baseline serum total testosterone, SHBG, and LH were assayed. Free testosterone was calculated using mass action equations. Incident stroke or transient ischemic attack (TIA) was recorded. Results: A first stroke or TIA occurred in 119 men (3.5%). Total and free testosterone concentrations in the lowest quartiles (<11.7 ...
250 citations
TL;DR: Lower free testosterone was independently associated with frailty at baseline and follow-up, and Randomized trials should explore whether testosterone therapy can prevent the development of frailty.
Abstract: Context: The prevalence of frailty increases, whereas testosterone decreases, as men age. Low testosterone may be a risk factor for development of this syndrome. Objective: Our objective was to determine whether testosterone levels are associated with frailty. Design: We conducted a prospective cohort study. Setting and Participants: Between 2001 and 2004, frailty was assessed in 3616 community-dwelling men aged 70–88 yr. Frailty was reassessed in 1586 men aged 76–93 yr in 2008–2009. Main Outcome Measures: Frailty was assessed with the FRAIL scale, comprising five domains: fatigue, difficulty climbing a flight of stairs, difficulty walking more than 100 m, more than five illnesses present, or weight loss greater than 5%. Testosterone, SHBG, and LH were assayed at baseline. Free testosterone was calculated using mass action equations. Results: At baseline, 15.2% of men (n = 548) were frail (at least three deficits), increasing to 23.0% (n = 364) at follow-up. At baseline, each 1 sd decrease in total or fre...
248 citations
TL;DR: The Health In Men Study (HIMS) arose out of a population-based randomized trial of screening for abdominal aortic aneurysms (AAAs) conducted in Perth, Western Australia in 1996–99 to assess whether screening reduced mortality from AAA.
Abstract: The Health In Men Study (HIMS) arose out of a population-based randomized trial of screening for abdominal aortic aneurysms (AAAs) conducted in Perth, Western Australia in 1996–99. Only men aged 65 years and over were recruited into the trial as AAAs are uncommon below this age and are six times more common in men than women. The aim of the trial was to assess whether screening reduced mortality from AAA. Secondary outcomes included assessments of the impact of screening on all-cause mortality and quality of life and a study of the rates of expansion of screen-detected AAAs.
218 citations
University of Southampton1, University College London2, Imperial College Healthcare3, Francis Crick Institute4, Boston University5, University of Edinburgh6, University of Oxford7, George Washington University8, Queen Mary University of London9, Harvard University10, University of Basel11, University of Western Australia12, Imperial College London13, French Institute of Health and Medical Research14, Icahn School of Medicine at Mount Sinai15, University of Birmingham16, University of London17, Federation of American Scientists18, Max Planck Society19, University of Bath20, Duke University21, University of Cambridge22
TL;DR: In this paper, the authors share their view of the current evidence-based consensus on COVID-19 and effective strategies to combat the risks posed by the second wave of the SARS-CoV-2.
189 citations
TL;DR: Low testosterone predicts mortality from CVD but is not associated with death from other causes, and prevention of androgen deficiency might improve cardiovascular outcomes but is unlikely to affect longevity otherwise.
Abstract: Context: Low testosterone is associated with all-cause mortality, but the relationship with cause-specific mortality is uncertain. Objective: Our objective was to explore associations between testosterone and its related hormones and cause-specific mortality. Design: This was a population-based cohort study. Setting and Participants: Demographic and clinical predictors of mortality, and testosterone, SHBG, and LH were measured from 2001–2004 in 3637 community-dwelling men aged 70–88 yr (mean, 77 yr). Main Outcome Measure: Cause of death was obtained via electronic record linkage until December 31, 2008. Results: During a mean follow-up period of 5.1 yr, there were 605 deaths. Of these, 207 [34.2%; 95% confidence interval (CI) = 30.4–38.1%] were due to cardiovascular disease (CVD), 231 to cancer (38.2%; 95% CI = 34.3–42.1%), 130 to respiratory diseases (21.5%; 95% CI = 18.2–24.8%), and 76 to other causes (12.6%; 95% CI = 9.9–15.2%). There were 39 deaths attributable to both cancer and respiratory diseases....
166 citations
Cited by
More filters
Saint Louis University1, French Institute of Health and Medical Research2, Charité3, University of Erlangen-Nuremberg4, The Catholic University of America5, Wright State University6, Columbia University7, University of Maryland, Baltimore8, University of Toronto9, Pennsylvania State University10, Dalhousie University11, University of Antwerp12, Johns Hopkins University13
TL;DR: For the purposes of optimally managing individuals with physical frailty, all persons older than 70 years and all individuals with significant weight loss (>5%) due to chronic disease should be screened for frailty.
2,751 citations
University of Cambridge1, Harvard University2, Peking University3, National Institutes of Health4, University of Oxford5, Curtin University6, Australian National University7, Imperial College London8, American Cancer Society9, University of Southern California10, Johns Hopkins University11, University of Sydney12, Vanderbilt University13, Chinese Center for Disease Control and Prevention14, University of Bristol15, Capital Medical University16, Erasmus University Rotterdam17, Yonsei University18, Fred Hutchinson Cancer Research Center19, University of Turin20, University of Glasgow21, University of North Carolina at Chapel Hill22, Shiga University of Medical Science23, Innsbruck Medical University24, International Agency for Research on Cancer25, University of Hong Kong26, Massey University27
TL;DR: The associations of both overweight and obesity with higher all-cause mortality were broadly consistent in four continents and supports strategies to combat the entire spectrum of excess adiposity in many populations.
1,731 citations
TL;DR: To help older people (>65 years) maintain and regain lean body mass and function, the PROT-AGE study group recommends average daily intake at least in the range of 1.2 g protein per kilogram of body weight per day.
1,700 citations
TL;DR: This study has validated the FRAIL scale in a late middle-aged African American population and is an excellent screening test for clinicians to identify frail persons at risk of developing disability as well as decline in health functioning and mortality.
Abstract: To validate the FRAIL scale. Longitudinal study. Community. Representative sample of African Americans age 49 to 65 years at onset of study. The 5-item FRAIL scale (Fatigue, Resistance, Ambulation, Illnesses, & Loss of Weight), at baseline and activities of daily living (ADLs), instrumental activities of daily living (IADLs), mortality, short physical performance battery (SPPB), gait speed, one-leg stand, grip strength and injurious falls at baseline and 9 years. Blood tests for CRP, SIL6R, STNFR1, STNFR2 and 25 (OH) vitamin D at baseline. Cross-sectionally the FRAIL scale correlated significantly with IADL difficulties, SPPB, grip strength and one-leg stand among participants with no baseline ADL difficulties (N=703) and those outcomes plus gait speed in those with no baseline ADL dependencies (N=883). TNFR1 was increased in pre-frail and frail subjects and CRP in some subgroups. Longitudinally (N=423 with no baseline ADL difficulties or N=528 with no baseline ADL dependencies), and adjusted for the baseline value for each outcome, being pre-frail at baseline significantly predicted future ADL difficulties, worse one-leg stand scores, and mortality in both groups, plus IADL difficulties in the dependence-excluded group. Being frail at baseline significantly predicted future ADL difficulties, IADL difficulties, and mortality in both groups, plus worse SPPB in the dependence-excluded group. This study has validated the FRAIL scale in a late middle-aged African American population. This simple 5-question scale is an excellent screening test for clinicians to identify frail persons at risk of developing disability as well as decline in health functioning and mortality.
1,110 citations
TL;DR: The evolution, controversies and challenges in defining sarcopenic obesity are discussed, and current body composition modalities used to assess this condition are presented and current treatment strategies are outlined.
Abstract: The prevalence of obesity in combination with sarcopenia (the age-related loss of muscle mass and strength or physical function) is increasing in adults aged 65 years and older. A major subset of adults over the age of 65 is now classified as having sarcopenic obesity, a high-risk geriatric syndrome predominantly observed in an ageing population that is at risk of synergistic complications from both sarcopenia and obesity. This Review discusses pathways and mechanisms leading to muscle impairment in older adults with obesity. We explore sex-specific hormonal changes, inflammatory pathways and myocellular mechanisms leading to the development of sarcopenic obesity. We discuss the evolution, controversies and challenges in defining sarcopenic obesity and present current body composition modalities used to assess this condition. Epidemiological surveys form the basis of defining its prevalence and consequences beyond comorbidity and mortality. Current treatment strategies, and the evidence supporting them, are outlined, with a focus on calorie restriction, protein supplementation and aerobic and resistance exercises. We also describe weight loss-induced complications in patients with sarcopenic obesity that are relevant to clinical management. Finally, we review novel and potential future therapies including testosterone, selective androgen receptor modulators, myostatin inhibitors, ghrelin analogues, vitamin K and mesenchymal stem cell therapy.
756 citations